Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Novartis - Caught on Camera

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme

The Guardian - AU

Carrie Ann Inaba's Delayed Diagnosis Highlights the Hidden Struggle of 4 Million Americans with Sjögren Disease

Sjögren disease affects 4 million Americans — 90% women — but takes an average of 4+ years to diagnose. Carrie Ann Inaba's story explains why, and what to do about it.

Medical Daily

3 European Stocks to Carry Investors Through the Back Half of 2026

European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

“Voice for Her Power” Unites Sectors to Advance Equity in Breast Cancer Care

The “Voice for Her Power: Empowered by Hope to Overcome Breast Cancer” alliance, led by the Thai Breast Cancer Community; Sabina Public Company Limited; The Sukosol Hotel Bangkok; and Novartis (Thailand) Limited, organized a collaborative initiative to pass on the voice of hope and ignite societal awareness about the importance…

Bangkok Post

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

The Guardian - UK

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand…

The Economic Times

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat

First malaria drug for babies is approved in ‘major public health milestone’

WHO prequalification of Coartem Baby means newborns can be safely treated rather than using medication for older children

The Guardian - UK

Carrie Ann Inaba shares health update after suffering medical emergency on flight

The ‘DWTS’ judge was on a flight to New York City for a campaign for her pharmaceutical company, Novartis

The Independent UK

Scotland becomes first part of UK to screen babies for rare muscle disease

All parents will now be offered spinal muscular atrophy screening for their newborns.

Evening Standard

Exclusive: Oro Labs, which is using AI to streamline companies' procurement processes, raises $100 million in fresh venture capital funding

Goldman Sachs Equity Growth and Brighton Park Capital lead the funding round for the company, which says it can reduce procurement process times from weeks to days or hours

Fortune

Novartis settles with Henrietta Lacks' estate over use of her 'stolen' cells to advance medicine

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine

The Independent UK

Tony Gonzalez Shares the One Question Travis Kelce Should Ask Himself Before Retiring

Gonzalez spoke to Sports Illustrated in an exclusive interview about Kelce’s NFL future.

Sports Illustrated

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent days from its CEO’s comments that the company will have essentially limited tariff exposure by mid-2026....

Fortune

Inside Big Pharma and VC’s big bet on AI: You wouldn’t ‘want to fly an airplane designed by hand, but all of our drugs are designed like that’

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

The Independent UK

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

International Business Times UK

Four Convicted in $600K Insider Trading Scheme — Don't Risk Your Savings

A former Chinook Therapeutics executive and his associates were convicted of insider trading, profiting over $600,000 from a major merger with Novartis.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.

Euronews

New malaria treatment could fight growing threat of drug resistance

Drugmaker Novartis said it will move quickly to ask regulators to approve the new medicine.

The Independent UK

2 new malaria treatments announced as drug resistance grows

Researchers are reporting two promising approaches to counteract malaria's growing drug resistance

The Independent UK

Scientists unveil new anti-malaria drug with ‘very high cure rate’

Treatment could be ‘the biggest advance in malaria treatment for decades,’ expert says

The Independent UK

Scientists create new anti-malaria drug with ‘very high cure rate’

Experts said they were "very excited" by the findings

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

1 2 3 4 5

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.